The Democratic Republic of Congo is currently facing an Ebola outbreak, prompting urgent action to develop vaccines specifically targeting the Bundibugyo ebolavirus. The Coalition for Epidemic Preparedness Innovations (CEPI) announced on Monday its commitment to fast-track the development of at least three vaccines, allocating roughly $62 million in funding to support manufacturing and testing efforts. Despite this financial boost, clinical trials for these vaccines are not expected to commence for several months. Currently, the only licensed vaccine for Ebola, Merck's Ervebo, is effective against the Zaire ebolavirus, leaving a gap in protection against Bundibugyo, which has historically caused limited outbreaks, with only two recorded instances in 2007 and 2012. The infrequent occurrence of the Bundibugyo virus has resulted in slower progress in developing vaccines and therapeutics compared to other filoviruses, such as Sudan ebolavirus and Marburg virus, which also pose significant health risks.